Shandong Weigao Blood Purification Products Co., Ltd. Class A

Shandong Weigao Blood Purification Products Co., Ltd. Class A

SSSE:603014
34.98
CNY
-0.09
(-0.26%)
2.06EPS
14.95P/E
21.39BMarket Cap
Mar 29Next Earn
Shandong Weigao Blood Purification Products Co., Ltd. Class A
SSE:603014
(Shanghai Stock Exchange)

Recent

price

34.98

P/E

ratio

14.95

div

yld

0.52%

ROIC.AI

2020
2021
2022
2023
2024
2025
TTM
CNY
7.93
8.29
9.46
9.51
9.7
9.53
11.06
Revenue per Share
0.89
0.74
0.87
1.19
1.21
1.22
2.06
Basic EPS, GAAP
0.14
0.3
1.24
0.15
1.06
1.6
- -
Free Cash Flow per Basic Share
0.14
0.12
0.05
- -
- -
0.17
0.18
Dividend per Share
9.56
10.5
12.61
13.87
15.12
17.04
15.65
Book Value per Share
8.7
9.63
11.8
13.87
14.32
16.35
15.19
Tangible Book Value per Share
333
351
362
371
371
395
488
Basic Weighted Avg Shares
2,642
2,911
3,426
3,532
3,604
3,769
5,401
Sales/Revenue/Turnover
17.67
12.05
11.3
43.74
15.45
14.78
21.06
Operating Margin (%)
164
201
240
164
241
248
- -
Depreciation Expense
297
260
315
442
449
482
1,005
Net Income, GAAP
18.83
18.63
13.91
15.6
17.65
16.24
14.48
Effective Tax Rate (%)
11.23
8.93
9.19
12.52
12.47
12.8
18.62
Profit Margin (%)
-54
-171
797
1,198
1,665
3,258
5,064
Working Capital
208
- -
2
1
3
- -
121
LT Debt
3,346
3,676
4,667
5,136
5,597
7,119
10,876
Total Equity
- -
6.04
7.18
9.29
8.58
7.71
11.25
Return on Invested Capital (%)
- -
7.58
7.82
9
8.37
7.59
11.31
Return on Capital (%)
- -
7.4
7.55
9.02
8.37
7.59
11.38
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
6
8
60
LT Borrowings
- -
- -
- -
LT Finance Leases
11
13
121
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
418
418
695
Market Capitalization
15,373
13,673
21,393

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
4,667
4,493
6,786
Cash, Cash Equivalents & STI
2,782
2,672
3,711
Accounts Receivable, Net
899
788
1,330
Inventories
815
854
1,413
Total Current Liabilities
1,259
1,156
1,722
Payables & Accruals
- -
- -
- -
ST Debt
6
8
60
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
16.61%
27.19%
Free Cash Flow
- -
208.91%
61.29%
Net Income, GAAP
- -
11.63%
7.33%
Sales/Revenue/Turnover
- -
7.51%
4.57%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
842
784
- -
- -
3,604
2025
896
869
- -
1,033
3,769
2026
904
854
2,610
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.28
0.26
- -
- -
1.21
2025
0.3
0.26
- -
0.34
1.22
2026
0.28
0.27
0.91
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
0.17
2026
- -
- -
0.13
- -
- -
Business
Shandong Weigao Blood Purification Products Co., Ltd. is a China-based medical technology company primarily engaged in the research, development, manufacture, and distribution of medical devices, consumables, and solutions for blood purification and advanced pharmaceutical packaging. Founded in 2004 and headquartered in Weihai, Shandong Province, China, the company operates as a core subsidiary of WEGO Group (Weigao Holding) and serves public and private hospitals, specialized nephrology centers, hemodialysis clinics, and biopharmaceutical enterprises across China and overseas markets. The company provides a comprehensive ecosystem spanning both hemodialysis and peritoneal dialysis clinical pathways as well as specialized drug delivery systems. Its primary product lines include: Hemodialysis Consumables, comprising high-flux and low-flux polysulfone membrane dialyzers, hemodialysis bloodline tubing sets, arteriovenous fistula puncture needles, hemodialysis dry powder, liquid dialysis concentrates, and equipment disinfectant fluids; Dialysis Equipment and Systems, comprising single-pump and double-pump hemodialysis machines, hemodiafiltration systems, continuous renal replacement therapy (CRRT) machines, automated peritoneal dialysis (APD) cyclers, and reverse osmosis water treatment units produced through internal research and strategic manufacturing partnerships with international medical device leaders such as Nikkiso and Terumo; Peritoneal Dialysis Products, comprising peritoneal dialysis solutions in non-PVC dual-bag packaging, automated peritoneal dialysis fluid sets, catheter connection kits, and digital home dialysis management platforms; and Advanced Pharmaceutical Packaging and Drug Delivery Systems, comprising pre-filled syringe (PFS) systems, automatic safety injection devices, pre-sterilized glass and polymer barrels, rigid needle shields, plunger stoppers, and biopharmaceutical process filtration consumables. In recent corporate developments, the company completed its initial public offering on the Main Board of the Shanghai Stock Exchange under the ticker 603014 in May 2025, raising approximately RMB 1.09 billion to finance manufacturing capacity expansion, automated warehouse construction, and research center upgrades. Following its listing, the company executed a major corporate reorganization and asset acquisition in 2026, issuing shares valued at RMB 8.51 billion to acquire a 100% equity stake in Shandong Weigao Purui Medical Packaging Co., Ltd. This strategic transaction established a dual-pillar operational structure combining blood purification technologies with high-barrier pharmaceutical packaging and biopharmaceutical filtration, accelerating the company's product diversification, supply chain integration, and commercial expansion in upstream bioprocessing markets.